Navigation Links
While Some New Agents Will Achieve Strong Sales, the Migraine Drug Market Will Decline $1.3 Billion by 2018 as Generic Erosion Takes Toll on Top-Selling Brands

WALTHAM, Mass., Aug. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although sales of emerging therapies will partially offset losses to generic competitors, the migraine drug market will decline from $4.7 billion in 2008 to $3.4 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Migraine finds that generic erosion of top-selling triptans such as GlaxoSmithKline's Imitrex/Imigran, prescribed for the acute treatment of migraine attacks, and Ortho-McNeil/Janssen-Cilag's anti-epileptic drug Topamax, used for migraine prophylaxis, will constrain the overall migraine market during the next decade and will exert increasing pressure on new products. However, the emergence of Merck's first-in-class calcitonin gene-related peptide receptor antagonist telcagepant as an alternative to triptan therapy will help counteract market losses -- according to the report, telcagepant will garner sales of $1.3 billion in 2018 in the world's major markets.

"Despite a delay in regulatory filing, we forecast that telcagepant will launch for the acute treatment of migraine in 2011 and will achieve blockbuster status, thanks to the drug's triptan-level efficacy, lack of cardiovascular risks, novel mechanism of action and strong marketing support," said Decision Resources Senior Analyst Jonathan Searles. "If the long-term safety of the drug is confirmed, telcagepant will offer a useful alternative for patients in whom the triptans are contraindicated as well as some patients who are refractory to, dissatisfied with or intolerant of triptan treatment. Moreover, we expect that some clinicians, including those who may still avoid triptans because of lingering safety concerns, will adopt telcagepant as an early choice among migraine-specific agents when first-line non-steroidal anti-inflammatory drugs and analgesics are insufficient."

The report also finds that two innovative reformulations of approved agents, Zogenix/Astellas Pharma's needle-free Sumavel DosePro and MAP Pharmaceuticals' inhaled Levadex will offer new non-invasive treatments. The report forecasts that these products will earn approximately $500 million combined by 2018. However, high cost, reimbursement challenges and patient preference for oral treatment are expected to limit the use of these unique drug-device combinations to a small minority of migraine patients.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

    Decision Resources                       Decision Resources, Inc.
    Christopher Comfort                      Elizabeth Marshall
    781-296-2597                             781-296-2563        

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FRC: Ryan Bill Increases Abortion While Claiming to Reduce Need for Abortion
2. While Health Clubs Say No to Canckles, Leading Podiatrists Say No to Toenail Fungus
3. NEUTROGENA(R) and BabyCenter Sun Survey Finds While Mom Knows Best She Can Learn Even More When it Comes to Sun Protection
4. Obesity While Young Boosts Pancreatic Cancer Risk
5. ICM Controls' Award-Winning Comfort Control Center Improves Comfort and Indoor Air Quality While Lowering Energy Costs
6. Almost Half of Those Over 60 Die While Waiting for Kidney Transplant
7. No Matter the Vehicle, Sending Text Messages While Driving Increases Risk of Accidents, Warns New York Auto Accident Lawyer
8. Language Technologies Introduces ReadSmart Edition Apps(TM) for the iPhone(TM) and iPod(R) Touch; Unique Apps Improve Ergonomics of Reading while Retaining Look and Design of Print Books
9. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
10. New Online Home Health Service Launched in California to Expand Direct Patient Care Time While Lowering Costs
11. While the Dangers of Sun Exposure are Widely Understood Americans Fall Short of Adequately Protecting Themselves from the Sun
Post Your Comments:
(Date:10/13/2017)... EDWARDSVILLE, Ill. (PRWEB) , ... ... ... University Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and ... educated healthcare professionals on guideline updates for the primary prevention of cardiovascular ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
Breaking Medicine Technology: